PRR

TAL Global Introduces Prepare - React - Recover (PRR)

Retrieved on: 
Tuesday, October 17, 2023
Public Policy, Government, Other Professional Services, Asset Management, Consulting, Public Safety, Professional Services, Technology, Security, PRR, Organization, Run Hide Fight, Running, Silicon, Risk assessment, Risk management, Leather, Gasoline, Run

TAL Global, a leading security consulting and risk assessment firm based in Silicon Valley, announces a new and more effective approach for handling active shooter and other violent crisis situations.

Key Points: 
  • TAL Global, a leading security consulting and risk assessment firm based in Silicon Valley, announces a new and more effective approach for handling active shooter and other violent crisis situations.
  • Known as Prepare-React-Recover, it is based on the best elements of Run, Hide, Fight, used for decades and supported by many law enforcement organizations.
  • With the Run, Hide, Fight methodology, in an active shooter situation, building users are to:
    Run out of the building.
  • However, according to Oscar Villanueva, COO of TAL Global, Run, Hide, Fight has at least two fundamental flaws.

TransCode Therapeutics Reports Successful Treatment of Preclinical Melanoma Tumors with its Immunotherapy Candidate, TTX-RIGA

Retrieved on: 
Monday, October 16, 2023
Neoplasm, Primary tumor, Transcoding, Doctor of Philosophy, Tumor microenvironment, GBM, RNA, Glioblastoma, PRR, Immunity, Therapy, Animal, Toxicity, RNA interference, Recurrence, Cancer, Melanoma, Immunotherapy, CRISPR, Growth, Immune system, TTX, Gene editing, Metastasis, Messenger, Vaccine

BOSTON, Oct. 16, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported successful treatment of preclinical melanoma tumors using its immunotherapy candidate, TTX-RIGA.

Key Points: 
  • BOSTON, Oct. 16, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported successful treatment of preclinical melanoma tumors using its immunotherapy candidate, TTX-RIGA.
  • TTX-RIGA is designed to work by binding to an intracellular receptor called RIG-I (retinoic acid-inducible gene I).
  • TransCode believes this could result in targeted activation of innate immunity in the tumor microenvironment.
  • TransCode believes that understanding how to recruit PRRs, such as RIG-I, in a tumor-selective manner is critical for clinical applications.

PROSPECT RIDGE RESOURCES ANNOUNCES DISCOVERY OF NEW MINERALIZED ZONE NAMED "LEON'S LEGACY" AT KNAUSS CREEK PROPERTY

Retrieved on: 
Wednesday, September 27, 2023
CSE, Atmosphere, Prospect Ridge Academy, Silver, FRA, Knauss, Gold, Anomaly, OTC, PRR, OED, Copper, News, Uranium mining, Mining, Dorreen station, Legacy

VANCOUVER, BC, Sept. 27, 2023 /PRNewswire/ - Prospect Ridge Resources Corp. (the "Company" or "Prospect Ridge") (CSE: PRR) (OTC: PRRSF) (FRA: OED) is pleased to announce the discovery of a new mineralized zone named "Leon's Legacy" on the Company's fully owned flagship Knauss Creek property, located 35km northeast of Terrace, British Columbia.

Key Points: 
  • VANCOUVER, BC, Sept. 27, 2023 /PRNewswire/ - Prospect Ridge Resources Corp. (the "Company" or "Prospect Ridge") (CSE: PRR) (OTC: PRRSF) (FRA: OED) is pleased to announce the discovery of a new mineralized zone named "Leon's Legacy" on the Company's fully owned flagship Knauss Creek property, located 35km northeast of Terrace, British Columbia.
  • Prospecting those led to the discovery of Leon's Legacy (named in honor of Leon Leblond (1930-2013) who prospected the property over a period of more than 25 years).
  • The new discovery is located approximately 900 m west-southwest and higher in elevation than the Dorreen Mine (see Figures 1 and 2).
  • This new discovery on the Knauss shows the tremendous potential of this property.

PROSPECT RIDGE RESOURCES ANNOUNCES HIGH GRADE SAMPLING RESULTS FROM DORREEN MINE AND EXPLORATION AT KNAUSS CREEK PROPERTY

Retrieved on: 
Thursday, September 14, 2023
Optimism, CSE, Vein, Zinc, Prospect Ridge Academy, Silver, Lead, FRA, Gold, OTC, PRR, OED, Iverson, Copper, Sampling, Doreen, Mining, Silviculture, Dorreen station, PB

Those results are part of an ongoing aggressive surface exploration campaign designed to follow up on historic showings and other targets across the entire property.

Key Points: 
  • Those results are part of an ongoing aggressive surface exploration campaign designed to follow up on historic showings and other targets across the entire property.
  • Sampling was completed at the Dorreen Mine that was developed in 1924, 1926 and in 1952.
  • We are very pleased with the exploration work in this area and these high-grade results will require future follow-up.
  • See location of the Dorreen Mine Target, within the Knauss Creek property in Figure 1.

TransCode Therapeutics Reports Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Glioblastoma

Retrieved on: 
Tuesday, June 6, 2023
Survival rate, CRISPR, Brain, Cell death, Temozolomide, GBM, Gene editing, Clinical trial, Cancer, Pharmacokinetics, Transcoding, DRS, Prognosis, University of Sydney School of Molecular Bioscience, RNA, Messenger, Glioblastoma, TMZ, Professor, Animal, Patient, IRB, Michigan State University, PRR, MN, RNA interference, Frontiers Media, Therapy, Recurrence, Breast cancer, Safety, TTX, Medical imaging, Vaccine, Frontiers

Treatment of human glioblastoma cells implanted in animals with the TTX-MC138 analogue, MN-anti-miR10b, inhibited tumor cell growth and induced cell death.

Key Points: 
  • Treatment of human glioblastoma cells implanted in animals with the TTX-MC138 analogue, MN-anti-miR10b, inhibited tumor cell growth and induced cell death.
  • This study comes on the heels of preclinical studies in breast cancer demonstrating complete regressions of metastatic disease.
  • “We believe that demonstrating additional successful preclinical results with TTX-MC138 is an important step in the development process.
  • TransCode Therapeutics recently received IRB approval for a first-in-human clinical trial with TTX-MC138 in patients with advanced solid cancers.

Aurinia Pharmaceuticals Announces Kidney Biopsies Sub-study Data from the LUPKYNIS® (voclosporin) AURORA 2 Clinical Trial Presented at Congress of Clinical Rheumatology East Conference

Retrieved on: 
Tuesday, May 9, 2023
Health, Biotechnology, Aurora, MMF, Nephrotoxicity, Overalls, Acute kidney injury, AURORA, EGFR, Conditional sentence, Glomerular filtration rate, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Proteinuria, Congress, CRR, Patient, Kidney, PRR, CNI, Conference, Safety, Biopsy, Pharmaceutical industry, Aurinia

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced data from the kidney biopsy sub-study of the AURORA clinical trial program (AURORA 1 and AURORA 2 Extension Study) was presented at the Congress of Clinical Rheumatology East Conference May 4 – 7, 2023.

Key Points: 
  • Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced data from the kidney biopsy sub-study of the AURORA clinical trial program (AURORA 1 and AURORA 2 Extension Study) was presented at the Congress of Clinical Rheumatology East Conference May 4 – 7, 2023.
  • To further characterize the long-term impact of LUPKYNIS on the kidney at the histologic level, repeat biopsies were collected from patients participating in the sub-study.
  • Specifically, repeat renal biopsies were obtained from 16 patients in the LUPKYNIS arm and 10 patients in the active control arm over 18 months from study entry.
  • “We are encouraged by these results,” said Dr. Greg Keenan, Chief Medical Officer of Aurinia.

Meet Kyana Wheeler, PRR's New Senior Director of Diversity, Equity, and Inclusion

Retrieved on: 
Wednesday, May 3, 2023
PRR, Policy, DEI, Wheeler, Organization, Race, Social, Social justice, City, Systems analysis, Security (finance), Management

SEATTLE, May 3, 2023 /PRNewswire/ -- PRR is excited to announce that Kyana Wheeler has joined the agency as the Senior Director of Diversity, Equity, and Inclusion (DEI).

Key Points: 
  • SEATTLE, May 3, 2023 /PRNewswire/ -- PRR is excited to announce that Kyana Wheeler has joined the agency as the Senior Director of Diversity, Equity, and Inclusion (DEI).
  • In her leadership role as Senior Director of DEI, Wheeler will lead PRR's DEI practice focusing on external equity efforts and working with clients to facilitate anti-racist work.
  • "We are thrilled to have Kyana on board to grow PRR's diversity, equity, and inclusion efforts with our clients and within our organization," said Malika Klingler, managing principal at PRR.
  • "Kyana has already made an impact during her short time at PRR, and we are excited to build upon our commitment to DEI and racial equity under her leadership."

Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Lupus Nephritis

Retrieved on: 
Tuesday, May 2, 2023
Health, Genetics, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Kidney disease, Lupus, Kidney failure, Autoimmunity, University, Chronic kidney disease, Allergy, Week, Christian democracy, University of California, Medicine, SLE, Dialysis, ORR, Proteinuria, ILT7, CRR, Patient, Risk, Rheumatology, Kidney, Kidney transplantation, PRR, B cell, African Americans, Disease, Pharmaceutical industry, LN, LN1

LN is a rare, autoimmune and inflammatory condition of the kidney and represents a common organ manifestation of systemic lupus erythematosus (SLE), a multisystem autoimmune disease.

Key Points: 
  • LN is a rare, autoimmune and inflammatory condition of the kidney and represents a common organ manifestation of systemic lupus erythematosus (SLE), a multisystem autoimmune disease.
  • Between 31 and 60 percent of SLE patients live with LN1 and in the United States, Horizon estimates that approximately 60,000 patients with LN are appropriate for treatment with novel therapies, including biologics.
  • There is a need to identify a more specific medicine for those with proliferative LN.”
    Approximately 210 participants who meet trial eligibility are expected to be enrolled.
  • As a part of our commitment to addressing better treatment options for autoimmune diseases, we are currently evaluating daxdilimab in SLE as well as a variety of other conditions.”

Indaptus Therapeutics’ Chief Scientific Officer Michael Newman, Ph.D. Named a Chair of the 4th STING & TLR-Targeting Therapies Summit

Retrieved on: 
Monday, May 1, 2023
Cytosol, Toxicity, Therapy, NOD, Infection, Clinical trial, Cancer, American Association for Cancer Research, Research, Neoplasm, Inflammation, Decoy, Patient, PRR, Poster, TLR, Pharmaceutical industry, Vaccine

The research discussed is also reflective of the recently presented poster during the American Association for Cancer Research, presented April 18th.

Key Points: 
  • The research discussed is also reflective of the recently presented poster during the American Association for Cancer Research, presented April 18th.
  • Dr. Newman’s second talk, “Pre-Clinical Anti-HBV Activity with a Passively Targeted, Multi-TLR, NOD and STING Agonist,” which features the Company’s infectious disease research on its Decoy platform will be held on May 11th at 2:30PM.
  • Deep diving into the role that the microbiome plays in innate immune regulation to provide a more holistic overview of how the STING and TLR activation are regulated.
  • The event will be held at the Hilton Boston Back Bay in Boston.

Pregnancy Outcomes with COVID-19 Vaccines Reviewed in Journal of American Physicians and Surgeons (AAPS)

Retrieved on: 
Tuesday, March 21, 2023
Vaccine, Vaccine Adverse Event Reporting System, Mortal Kombat, AE, Vaccination, Physician, AAPS, Aes, COVID-19, Influenza vaccine, Association of American Physicians and Surgeons, Person, CDC, Influenza, Food and Drug Administration, Journal, Causality, Fertility, Miscarriage, Stillbirth, VAERS, PRR, Pregnancy, FDA, Food, Pharmaceutical industry, Surgeon

Their summary is published in the spring issue of the peer-reviewed Journal of American Physicians and Surgeons.

Key Points: 
  • Their summary is published in the spring issue of the peer-reviewed Journal of American Physicians and Surgeons.
  • Influenza vaccines were chosen as the control group because the CDC first approved influenza vaccines for pregnant women in 1997.
  • The study period provides 282 months of data for the influenza vaccine and 18 months of data for the COVID-19 vaccines.
  • The Journal of American Physicians and Surgeons is published by the Association of American Physicians and Surgeons (AAPS) , a national organization representing physicians in all specialties since 1943.